FDA approves Perrigo’s generic Suprep

SILVER SPRING, Md. — The Food and Drug Administration has approved Perrigo’s generic of Suprep (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution, the company announced Tuesday. The drug is indicated as a treatment for cleansing of the colon in preparation for colonoscopy in adults. 

 

The drug had U.S. sales of $178 million for the 12 months ended July 2016. 

 

Alongside its generic approval, Perrigo announced that it had been sued by Galderma Laboratories and Nestle Skin Health over a filed abbreviated new drug application for Mirvaso (brimonidine) topical gel 33%. 

 

“These accomplishments demonstrate Perrigo's commitment to our customers and consumers around the world,” Perrigo CEO John Hendrickson said. “The team's ability to develop and bring to market high quality, value alternatives in important treatment categories is what continues to drive Perrigo's mission of providing Quality Affordable Healthcare Products around the world.”